Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Biol. Res ; 49: 1-13, 2016. ilus, graf, tab
Artículo en Inglés | LILACS | ID: biblio-950869

RESUMEN

BACKGROUND: Computer-based technology is becoming increasingly essential in biological research where drug discovery programs start with the identification of suitable drug targets. 2-Methoxyestradiol (2ME2) is a 17ß-estradiol metabolite that induces apoptosis in various cancer cell lines including cervical cancer, breast cancer and multiple myeloma. Owing to 2ME2's poor in vivo bioavailability, our laboratory in silico-designed and subsequently synthesized a novel 2ME2 analogue, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol), using receptor- and ligand molecular modeling. In this study, the biological effects of ESE-15-ol (180 nM) and its parent molecule, 2ME2 (1 µM), were assessed on morphology and apoptosis induction in cervical cancer cells. RESULTS: Transmission electron microscopy, scanning electron microscopy and polarization-optical transmitted light differential interference contrast (PlasDIC) images demonstrated morphological hallmarks of apoptosis including apoptotic bodies, shrunken cells, vacuoles, reduced cell density and cell debris. Flow cytometry analysis showed apoptosis induction by means of annexin V-FITC staining. Cell cycle analysis showed that ESE-15-ol exposure resulted in a statistically significant increase in the G2M phase (72%) compared to 2ME2 (19%). Apoptosis induction was more pronounced when cells were exposed to ESE-15-ol compared to 2ME2. Spectrophotometric analysis of caspase 8 activity demonstrated that 2ME2 and ESE-15-ol both induced caspase 8 activation by 2- and 1.7-fold respectively indicating the induction of the apoptosis. However, ESE-15-ol exerted all of the above-mentioned effects at a much lower pharmacological concentration (180 nM) compared to 2ME2 (1 µM physiological concentration). CONCLUSION: Computer-based technology is essential in drug discovery and together with in vitro studies for the evaluation of these in silico-designed compounds, drug development can be improved to be cost effective and time consuming. This study evaluated the anticancer potential of ESE-15-ol, an in silico-designed compound in vitro. Research demonstrated that ESE-15-ol exerts antiproliferative activity accompanied with apoptosis induction at a nanomolar concentration compared to the micromolar range required by 2ME2. This study is the first study to demonstrate the influence of ESE-15-ol on morphology, cell cycle progression and apoptosis induction in HeLa cells. In silico-design by means of receptor- and ligand molecular modeling is thus effective in improving compound bioavailability while preserving apoptotic activity in vitro.


Asunto(s)
Humanos , Femenino , Sulfonamidas/farmacología , Inhibidores de Anhidrasa Carbónica/farmacología , Neoplasias del Cuello Uterino/tratamiento farmacológico , Diseño Asistido por Computadora , Estradiol/análogos & derivados , Antineoplásicos/farmacología , Factores de Tiempo , Células HeLa , Microscopía Electrónica de Rastreo , Ciclo Celular/efectos de los fármacos , Ciclo Celular/fisiología , Células Cultivadas , Neoplasias del Cuello Uterino/patología , Reproducibilidad de los Resultados , Apoptosis/efectos de los fármacos , Medios de Cultivo , Microscopía Electrónica de Transmisión , Estradiol/farmacología , Caspasa 8/metabolismo , Citometría de Flujo/métodos , 2-Metoxiestradiol , Microscopía de Polarización
2.
Biol. Res ; 47: 1-7, 2014. ilus, graf
Artículo en Inglés | LILACS | ID: biblio-950735

RESUMEN

BACKGROUND: Novel, in silico-designed anticancer compounds were synthesized in our laboratory namely, 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-17-ol (ESE-15-ol) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (ESE-16). These compounds were designed to have improved bioavailability when compared to their source compound, 2-methoxyestradiol. This theoretically would be due to their increased binding affinity to carbonic anhydrase II, present in erythrocytes. Since the novel compounds under investigation are proposed to be transported within erythrocytes bound to carbonic anhydrase II, the morphological effect which they may exert on whole blood and erythrocytes is of great significance. A secondary outcome included revision of previously reported procedures for the handling of the whole blood sample. The purpose of this study was twofold. Firstly, the ultrastructural morphology of a healthy female's erythrocytes was examined via scanning electron microscopy (SEM) after exposure to the newly in silico-designed compounds. Morphology of erythrocytes following exposure to ESE-15-ol and ESE-16 for 3 minutes and 24 hours at 22°C were described with the use of SEM. The haemolytic activity of the compounds after 24 hours exposure were also determined with the ex vivo haemolysis assay. Secondly, storage conditions of the whole blood sample were investigated by determining morphological changes after a 24 hour storage period at 22°C and 37°C. RESULTS: No significant morphological changes were observed in the erythrocyte morphology after exposure to the novel anticancer compounds. Storage of the whole blood samples at 37°C for 24 hours resulted in visible morphological stress in the erythrocytes. Erythrocytes incubated at 22°C for 24 hours showed no structural deformity or distress. CONCLUSIONS: From this research the optimal temperature for ex vivo exposure of whole blood samples to ESE-15-ol and ESE-16 for 24 hours was determined to be 22°C. Data from this study revealed the potential of these compounds to be applied to ex vivo study techniques, since no damage occurred to erythrocytes ultrastructure under these conditions. As no structural changes were observed in erythrocytes exposed to ESE-15-ol and ESE-16, further ex vivo experiments will be conducted into the potential effects of these compounds on whole blood. Optimal incubation conditions up to 24 hours for whole blood were established as a secondary outcome.


Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Sulfonamidas/farmacología , Simulación por Computador , Inhibidores de Anhidrasa Carbónica/farmacología , Eritrocitos/efectos de los fármacos , Estradiol/análogos & derivados , Estrenos/farmacología , Antineoplásicos/farmacología , Sulfonamidas/toxicidad , Sulfonamidas/farmacocinética , Temperatura , Inhibidores de Anhidrasa Carbónica/farmacocinética , Disponibilidad Biológica , Microscopía Electrónica de Rastreo , Proteínas Portadoras/farmacología , Proteínas Portadoras/farmacocinética , Anhidrasa Carbónica II/efectos de los fármacos , Investigación Cualitativa , Eritrocitos/ultraestructura , Estradiol/toxicidad , Estradiol/farmacología , Estradiol/farmacocinética , Estrenos/farmacocinética , Descubrimiento de Drogas , Hemólisis/efectos de los fármacos , Antineoplásicos/farmacocinética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA